VXX vs XBI
iPath Series B S&P 500 VIX Short-Term Futures ETN vs SPDR S&P Biotech ETF
VXX$21.58
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
XBI$164.28
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.36%
Quick take
- • XBI has the lower expense ratio at 0.35% vs 0.89% for VXX.
- • XBI pays a higher dividend yield (0.36%).
Side-by-side metrics
| Metric | VXX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.89% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $441M | $10.73B |
YTD return | -16.85% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 45.83 | 1.10 |
P/E ratio | — | — |
Last price | $21.58 | $164.28 |
Inception | — | — |
Issuer | Barclays | State Street |
VXX top holdings
Holdings data unavailable for VXX.
XBI top holdings
Top holdings · XBI
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
Sector breakdown · XBI
Financial Services0.5%
Healthcare99.5%
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $441M in assets under management, an expense ratio of 0.89%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.